Category: PR2133

How does ageing impact on drug dosing

Physiological changes associated with ageing can impact the appropriate dosing for many drugs. General principles to keep in mind include:

Absorption:

  • Absorption usually does not change with normal ageing.

Distribution:

  • Concentrations of water-soluble drugs are usually higher as there is less water and so a lower volume of distribution.
  • Concentrations of free or active (unbound) drug are usually higher due to lower serum proteins.

Metabolism:

  • The half-life of lipophilic drugs is usually higher due to more fat resulting in an increased volume of distribution and prolonged duration of action.
  • There is slower Phase I metabolism (e.g., oxidation, reduction and dealkylation) due to cytochrome P450 pathways resulting in higher levels of drugs dependent on these pathways for metabolism (e.g., warfarin).
  • However, Phase II reactions (e.g., conjugation, acetylation, and methylation) are usually unchanged in normal ageing.
  • There is a greater risk of drug-drug interactions in metabolism due to increased numbers of drugs for multiple medical problems.

Excretion:

  • Hepatic excretion may be impaired.
  • Renal clearance may be impaired, and serum creatinine may not be an accurate reflection of renal clearance in elderly patients due to decreased lean body mass (muscle mass).
  • Active drug metabolites can accumulate, resulting in prolonged therapeutic actions and a greater risk of adverse effects.

There is also increased susceptibility to adverse effects. Older adults are also more likely to have multiple chronic medical problems, and disease states can result in physiological changes:

  • Cardiac disease can result in impaired cardiac output resulting in impaired ADME and greater susceptibility to cardiac adverse effects.
  • Liver or kidney disease can decrease metabolism and excretion, reducing drug clearance.
  • Neurological diseases result in greater sensitivity to neurological adverse effects due to diminished neurotransmitter levels and/or impaired cerebral blood flow.

 

What is the difference between pharmacology and pharmacy?

What is the difference between pharmacology and pharmacy?

Pharmacology is the study of the sources, uses, and mechanisms of action of drugs. That is what the body does to drugs (pharmacokinetics) and what drugs do to the body (pharmacodynamics).

Pharmacy is the science or practice of the preparation, formulation,  and dispensing of medicinal drugs.

 

Why is monotherapy with LABAs contraindicated in asthma?

Why is the chronic use of long-acting beta agonists (LABAs) alone without the concomitant use of an inhaled corticosteroid contraindicated in asthma? What about short-acting beta agonists (SABAs), can they be used without taking an inhaled corticosteroid at the same time?

Activation of β2-adrenoceptor promotes bronchodilation. β2-adrenoceptor agonists are the most potent bronchodilators in current clinical use. Inhaled short-acting beta agonists (SABAs), for example salbutamol (known as albuterol in the USA) have a bronchodilator effect that lasts for 4 to 6 hours, while long-acting beta agonists (LABAs), for example salmeterol, have a  bronchodilator effect that lasts for 12 to 24 hours (depending upon the drug). SABAs are used to relieve acute bronchoconstriction. Use of a SABA can be a life-saving intervention during an asthma attack. In contrast, LABAs are used chronically to mainain bronchodilation improving airway function and controlling occurance of symptoms.

Chronic use of LABAs causes tolerance due to downregulation of β2-adrenoceptors. This is associated with an increased risk of mortality in patients with asthma. Therefore the use of LABAs alone is contraindicated. The downregulation of β2-adrenoceptors by chronic use of LABAs can impair the response to SABAs when they are need for acutre relief of symptoms during an asthma attack.

Continue reading

Practical guide to good prescribing?

I have completed my pre-clinical pharmacology studies. The lecturers helped me to build a framework of understanding of the pharmacological mechanisms of the major drug classes. This has given me a solid foundation of understanding of the pharmacology of the various drug classes on which I can continue to build as I learn more. But now going into my clinical years I feel lost about how to apply this knowledge in practice for clinical pharmacology. Where can I find a clear and practical guide on how to go about good prescribing in clinical practice?

The WHO has an excellent Guide to Good Prescribing – A Practical Manual.

You are likely not alone in feeling a little lost as you progress from pre-clinical theoretical understanding of pharmacology to practical application of clinical pharmacology. As the WHO Guide to Good Prescribing describes in its introduction on “Why you need this book”: “At the start of clinical training most medical students find that they don’t have a very clear idea of how to prescribe a drug for their patients or what information they need to provide. This is usually because their earlier pharmacology training has concentrated more on theory than on practice. The material was probably ‘drug-centred’, and focused on indications and side effects of different drugs. But in clinical practice the reverse approach has to be taken, from the diagnosis to the drug.”

This does not mean that your pre-clinical pharmacology training was wrong. It is just that finishing your pre-clinical years does not mean that you have finished learning pharmacology. Now in your clinical years, you need to learn clinical pharmacological applications and good prescribing. Your pharmacological learning should never end.  Throughout the rest of your career, you will have to continue to update your pharmacological knowledge as new drugs are approved or evidence-based best medical practice changes with new information. That is why your pre-clinical pharmacological training focused on helping you to build a solid foundation of a knowledge framework into which you can continue to integrate new pharmacological understanding as you come across new drugs in clinical practice.

 

Why does overdose of salbutamol cause tachycardia?

Salbutamol is beta-2 adrenoceptor agonist used to treat the respiratory symptoms of asthma. We learned that it is beta-2 adrenoceptors in the lungs and beta-1 adrenoceptors in the heart. So why does overdose of salbutamol cause a rapid heart rate? 

Activation of beta-2 adrenoceptors in the airways promotes bronchodilation, reduction of airway secretions, and stimulation of mucociliary clearance.  Thus beta-2 adrenoceptor agonists are used in treating the symptoms of asthma. Meanwhile, in the heart, beta-1 adrenoceptor activation has inotropic and chronotropic effects, increasing contractile force and heart rate, respectively.

For the treatment of the symptoms of asthma without causing cardiovascular adverse effects, selective beta-2 adrenoceptor agonists would be the preferred.  Salbutamol is an example of a selective beta-2 adrenoceptor agonist. However, the beta-2 and beta-1 adrenoceptors are very similar, so salbutamol is not entirely selective. Salbutamol shows dose-dependent selectivity for beta-2 adrenoceptors but does still act as a weak beta-1 agonist.  Thus, on overdose, the beta-1 agonist activity of salbutamol can start to cause cardiovascular adverse effects by activating beta-1 adrenoceptors in the heart to increase the force and rate of heart contractions.

Neuropsychiatric adverse events with leukotriene inhibitors

Neuropsychiatric adverse events are reported in some patients taking leukotriene inhibitors (e.g. montelukast and zileuton)

In 2009, the USA Food and Drug Administration (FDA) reported on an investigation of neuropsychiatric adverse events associated with the leukotriene pathway inhibitors, both the leukotriene receptor antagonists (e.g. montelukast) and the 5-lipoxygenase inhibitor (zileuton) (1).  It was concluded that “reported neuropsychiatric events include postmarket cases of agitation, aggression, anxiousness, dream abnormalities and hallucinations, depression, insomnia, irritability, restlessness, suicidal thinking and behavior (including suicide), and tremor”. The FDA, therefore, issued the following advice to patients and healthcare professionals:

Advice to patients and healthcare professionals

  • Patients and healthcare professionals should be aware of the potential for neuropsychiatric events with these medications.
  • Patients should talk with their healthcare providers if these events occur.
  • Healthcare professionals should consider discontinuing these medications if patients develop neuropsychiatric symptoms.”

Reference:
(1) Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)

 

Why is guaifenesin so difficult to spell?

Even among drugs names that are often difficult to pronounce or spell, guaifenesin stands out for tripping up more students on spelling in exams than other drug names. Why is “guaifenesin” spelt this way? 

Breaking “guaifenesin” up into “guai” and “fenesin” may help us to remember how to spell the word. It is the “guai” that in particular seems unnatural in English and is difficult to spell. Perhaps understanding the origins of the “guai” in “guaifenesin” can help us to remember how to spell the word.

The “guai” in “guaifenesin” comes from the word “guaiac”. Guaiac has been an English word since at least 1558, some say 1533. It is the common name for trees of the genus Guaiacum.  The word originates from the Maipurean language spoken by the native Taínos people of the Bahamas. “Guaiac” has the honour of being the first American language word adopted into the English language.  The guaiac is famous for being the source of the hardest wood known. The resin and bark of the guaiac were also used in traditional medicine for coughs and various other conditions.  Guaifenesin is the active compound in the treatment of coughs isolated from guaiac resin and bark.

Guaifenesin was also formerly spelt “guaiphenesin”. It is one of the few drugs for which the American contraction of “ph” to “f” is now adopted for the official international nonproprietary name of the drug. The chemical name for guaifenesin is glyceryl guaiacolate.

Interestingly, guaiac resin also made another significant contribution to medicine. A phenolic compound derived from guaiac tree resin has also been used in the faecal occult blood test (FOBT).  The presence of haeme from blood causes this compound to form a coloured product when exposed to hydrogen peroxide.

 

Fluticasone and adrenal suppression

Why is fluticasone more frequently associated with adrenal suppression than other inhaled corticosteroids for the treatment of asthma?

Inhaled corticosteroids are highly effective in controlling asthma but have been associated with adrenal suppression.  Adrenal insufficiency can occur chronically from systemic absorption of the corticosteroid resulting in feedback suppression of endogenous glucocorticoid production. Suppression can also occur acutely if the patient abruptly discontinues treatment rather than gradually stepping down the corticosteroid dose. The suppressed adrenal system is then unable to respond adequately to stressful stimuli such as trauma and infection. Signs and symptoms of adrenal suppression can include anorexia, abdominal pain, weight loss, fatigue, headache, nausea, vomiting, decreased level of consciousness, hypoglycaemia and seizures. 

Although adrenal suppression can occur with any inhaled corticosteroid, fluticasone, in particular, has  been most frequently associated with adrenal insufficiency.  This is likely due to the greater potency of fluticasone, which results in a greater risk of prescription of higher-than-licensed doses of fluticasone (1). In particular, children, the elderly and other patients requiring dose adjustment may be at increased risk.  It is also important for prescribers to remember that beyond a certain limit, increasing the dose of inhaled corticosteroids offers minimal benefit but increases the risk of systemic adverse effects” (1). 

Reference:
(1) WHO Drug Information Vol. 17, No. 4, 2003, Safety and Efficacy Issues, Fluticasone and adrenal suppression [accessed 4 Feb 2017]

Useful Resources on Asthma Medication

Links to useful resources on asthma medication from the National Asthma Council Australia:

Asthma & COPD Medications Chart

Inhaler Technique Checklists

 

© 2024 PharmaNUS

Theme by Anders NorenUp ↑

Skip to toolbar